Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.72 |
| ▸ | CA1 | P00915 | 7/20 | 0.72 |
| ▸ | CA9 | Q16790 | 4/20 | 0.72 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911368 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL14414834 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL8248779 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL23902622 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1170798 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL23902613 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL14419747 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL9911234 | 1.00 | CA2 (0.72) | CA2CA1CA9CA12CA4 | |
| SCHEMBL5665101 | 0.86 | CA2 (0.81) | CA2CA1CA9CA12CA4 | |
| SCHEMBL2757717 | 0.86 | CA2 (0.81) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20110288287-A1 | Halogen Substituted Saccharide, Method for Producing Same, Reaction Composition of Same and Device for Producing Same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2386562-A1 | HALOGEN-SUBSTITUTED SACCHARIDE, METHOD FOR PRODUCING SAME, REACTION COMPOSITION OF SAME AND DEVICE FOR PRODUCING SAME | National Institute of Advanced Industrial Science And Technology (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-8039752-B2 | Heat dissipation structure of a print circuit board | KEIHIN CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288287-A1 | Halogen Substituted Saccharide, Method for Producing Same, Reaction Composition of Same and Device for Producing Same | FTO, SETD7, SETD2 | CA2 367/4885CA1 41/4885CA9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.